Christopher Lord

Christopher Lord

UNVERIFIED PROFILE

Are you Christopher Lord?   Register this Author

Register author
Christopher Lord

Christopher Lord

Publications by authors named "Christopher Lord"

Are you Christopher Lord?   Register this Author

100Publications

3570Reads

47Profile Views

Translational genomics of ovarian clear cell carcinoma.

Semin Cancer Biol 2019 Nov 4. Epub 2019 Nov 4.

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK; Division of Molecular Pathology, The Institute of Cancer Research, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semcancer.2019.10.025DOI Listing
November 2019

Longitudinal analysis of a secondary BRCA2 mutation using droplet digital PCR.

J Pathol Clin Res 2019 Oct 2. Epub 2019 Oct 2.

The CRUK Gene Function Laboratory and Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cjp2.146DOI Listing
October 2019

Beyond DNA repair: the novel immunological potential of PARP inhibitors.

Mol Cell Oncol 2019 13;6(2):1585170. Epub 2019 Mar 13.

Faculté de médicine, Université Paris Saclay, Université Paris-Sud, Le Kremlin Bicêtre, France.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/23723556.2019.1
Publisher Site
http://dx.doi.org/10.1080/23723556.2019.1585170DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512907PMC
March 2019

Dissecting PARP inhibitor resistance with functional genomics.

Curr Opin Genet Dev 2019 02 5;54:55-63. Epub 2019 Apr 5.

The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gde.2019.03.001DOI Listing
February 2019

Identifying Genetic Dependencies in Cancer by Analyzing siRNA Screens in Tumor Cell Line Panels.

Methods Mol Biol 2018 ;1711:83-99

The Breast Cancer Now Toby Robins Breast Cancer Research Centre and CRUK Gene Function Laboratory, The Institute of Cancer Research, London, SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7493-1_5DOI Listing
October 2018

Synthetic Lethality and Cancer - Penetrance as the Major Barrier.

Trends Cancer 2018 10 15;4(10):671-683. Epub 2018 Sep 15.

Breast Cancer Now Toby Robins Research Centre and Cancer Research UK (CRUK) Gene Function Laboratory, Institute of Cancer Research (ICR), London SW3 6JB, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2018.08.003DOI Listing
October 2018

Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Nat Rev Clin Oncol 2018 09;15(9):564-576

The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0055-6DOI Listing
September 2018

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

Nat Commun 2018 05 22;9(1):2016. Epub 2018 May 22.

The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-04466-4
Publisher Site
http://dx.doi.org/10.1038/s41467-018-04466-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964205PMC
May 2018

Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer.

Cancer Discov 2018 03;8(3):272-275

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-18-0091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372062PMC
March 2018

Hypercalcaemia secondary to ectopic parathyroid hormone expression in an adolescent with metastatic alveolar rhabdomyosarcoma.

Pediatr Blood Cancer 2018 Jan 26;65(1). Epub 2017 Aug 26.

Department of Paediatric Oncology, University Hospital Southampton Foundation Trust, Southampton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26778DOI Listing
January 2018

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer.

Cell Rep 2018 01;22(5):1185-1199

University of Arizona Cancer Center, Tucson, AZ 85724, USA; Department of Medicine, University of Arizona, Tucson, AZ 85724, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22111247183003
Publisher Site
http://dx.doi.org/10.1016/j.celrep.2018.01.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967622PMC
January 2018

Directing the use of DDR kinase inhibitors in cancer treatment.

Expert Opin Investig Drugs 2017 Dec 14;26(12):1341-1355. Epub 2017 Oct 14.

a The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research Centre , The Institute of Cancer Research , London , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2017.1389895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157710PMC
December 2017

A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events.

Cell Syst 2017 10 11;5(4):399-409.e5. Epub 2017 Oct 11.

The Breast Cancer Now Toby Robins Breast Cancer Research Centre and CRUK Gene Function Laboratory, The Institute of Cancer Research, London SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cels.2017.09.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5660599PMC
October 2017

Modeling Therapy Resistance in -Mutant Cancers.

Mol Cancer Ther 2017 09 15;16(9):2022-2034. Epub 2017 Jun 15.

The CRUK Gene Function Laboratory and The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/lookup/doi/10.1158/1535-7163.MCT
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-17-0098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157714PMC
September 2017

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer.

Cell Syst 2017 07 12;5(1):82-86.e3. Epub 2017 Jul 12.

Systems Biology Ireland, University College Dublin, Belfield, Dublin, Ireland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cels.2017.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531859PMC
July 2017

Nup100 regulates replicative life span by mediating the nuclear export of specific tRNAs.

RNA 2017 03 8;23(3):365-377. Epub 2016 Dec 8.

Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37240, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1261/rna.057612.116DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5311497PMC
March 2017

PARP inhibitors: Synthetic lethality in the clinic.

Science 2017 03 16;355(6330):1152-1158. Epub 2017 Mar 16.

University of California, San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, 1450 Third Street, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://www.sciencemag.org/lookup/doi/10.1126/science.aam7344
Publisher Site
http://dx.doi.org/10.1126/science.aam7344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175050PMC
March 2017

The appendix: a spectrum of benign and malignant disease.

Br J Hosp Med (Lond) 2017 Feb;78(2):82-87

Consultant Radiologist, Department of Radiology, Salisbury NHS Foundation Trust, Salisbury, Wiltshire SP2 8BJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/hmed.2017.78.2.82DOI Listing
February 2017

PARP inhibitor combination therapy.

Crit Rev Oncol Hematol 2016 Dec 31;108:73-85. Epub 2016 Oct 31.

UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.10.010DOI Listing
December 2016

Synthetic lethality: the road to novel therapies for breast cancer.

Endocr Relat Cancer 2016 10 15;23(10):T39-55. Epub 2016 Aug 15.

The CRUK Gene Function Laboratory and Breast Cancer Now Toby Robins Research CentreThe Institute of Cancer Research, London, UK

View Article

Download full-text PDF

Source
https://erc.bioscientifica.com/view/journals/erc/23/10/T39.x
Publisher Site
http://dx.doi.org/10.1530/ERC-16-0228DOI Listing
October 2016

Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.

Mol Cancer Ther 2016 07 30;15(7):1472-84. Epub 2016 Jun 30.

The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0554DOI Listing
July 2016

Overexpression of MYB drives proliferation of CYLD-defective cylindroma cells.

J Pathol 2016 06 21;239(2):197-205. Epub 2016 Apr 21.

Sahlgrenska Cancer Centre, Department of Pathology, University of Gothenburg, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869681PMC
June 2016

BRCAness revisited.

Nat Rev Cancer 2016 Feb 18;16(2):110-20. Epub 2016 Jan 18.

UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrc.2015.21
Publisher Site
http://dx.doi.org/10.1038/nrc.2015.21DOI Listing
February 2016

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

N Engl J Med 2015 Oct;373(18):1697-708

From the Institute of Cancer Research (J.M., S.C., S.S., S.M., H.M., R.P.-L., D.N.R., A.O., N.T., G.B., N.P., P.F., A.G., I.F., C.P., G.S., D.B., J.G., Z.Z., C.T.W., R.F., R.R., B.E., G.F., D. Roda, W.Y., R.B., H.P., R.A., A.S., R.E., G.A., C.J.L., A.A., E.H., J.S.B.), the Royal Marsden NHS Foundation Trust (J.M., S.S., R.P.-L., A.O., N.T., D.B., Z.Z., R.F., D. Roda, R.E., G.A., J.S.B.), and University College London Hospital (U.M.), London, Queen's University, Belfast (S.J.), University of Leeds, Leeds (C.R.), Churchill Hospital, Oxford (A.P.), University of Liverpool, Liverpool (S.H.), Beatson West of Scotland Cancer Centre, Glasgow (R.J.), and Christie Hospital, Manchester (T.E.) - all in the United Kingdom; the University of Michigan, Ann Arbor (D. Robinson, Y.-M.W., X.C., L.P.K., F.Y.F., A.M.C.); Weill Cornell Medical College, New York (M.A.R.); and Thomas Jefferson University, Philadelphia (K.E.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506859DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228595PMC
October 2015

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Annu Rev Med 2015 17;66:455-70. Epub 2014 Oct 17.

The Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, United Kingdom and.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1146/annurev-med-050913-022545DOI Listing
September 2015

Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.

Cancer Discov 2015 May 13;5(5):488-505. Epub 2015 Mar 13.

Breakthrough Breast Cancer Research Unit, King's College London, London, United Kingdom. Department of Research Oncology, King's Health Partners AHSC, Life Sciences and Medicine, King's College London, London, United Kingdom. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490184PMC
May 2015

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.

Oncotarget 2015 May;6(13):10746-58

The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4484416PMC
http://dx.doi.org/10.18632/oncotarget.3628DOI Listing
May 2015

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways.

Mol Cancer Ther 2015 Apr 11;14(4):865-76. Epub 2015 Feb 11.

CRUK Gene Function Laboratory, Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Breast Unit, Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/content/14/4/865.full.pdf
Web Search
http://mct.aacrjournals.org/content/molcanther/early/2015/02
Web Search
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-14
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-14-0845DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485454PMC
April 2015

Altering nuclear pore complex function impacts longevity and mitochondrial function in S. cerevisiae.

J Cell Biol 2015 Mar;208(6):729-44

Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1083/jcb.201412024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362458PMC
March 2015

The cylindromatosis gene product, CYLD, interacts with MIB2 to regulate notch signalling.

Oncotarget 2014 Dec;5(23):12126-40

The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322962PMC
http://dx.doi.org/10.18632/oncotarget.2573DOI Listing
December 2014

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Cancer Res 2014 Oct 28;74(20):5866-77. Epub 2014 Aug 28.

Department of Oncology, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, Liverpool, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-0806DOI Listing
October 2014

DAISY: picking synthetic lethals from cancer genomes.

Cancer Cell 2014 Sep;26(3):306-308

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.08.008DOI Listing
September 2014

NLK is a novel therapeutic target for PTEN deficient tumour cells.

PLoS One 2012 29;7(10):e47249. Epub 2012 Oct 29.

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0047249PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483146PMC
August 2014

An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor.

Cancer Discov 2014 Mar 11;4(3):304-17. Epub 2014 Feb 11.

1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research; 2Cardiovascular Division, King's College London, British Heart Foundation Centre for Research Excellence, James Black Centre; and 3Division of Molecular Biosciences, Imperial College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0287DOI Listing
March 2014

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

Cancer Res 2014 Jan 15;74(1):287-97. Epub 2013 Nov 15.

Authors' Affiliations: The CRUK Gene Function Laboratory, Functional Genomics Laboratory, Breakthrough Breast Cancer Research Centre, and Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-13-2541DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886090PMC
January 2014

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Nat Med 2013 Nov 7;19(11):1381-8. Epub 2013 Oct 7.

The Breakthrough Breast Cancer Research Centre and Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nm.3369
Publisher Site
http://dx.doi.org/10.1038/nm.3369DOI Listing
November 2013

Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.

Mol Cancer Ther 2013 Oct 24;12(10):2135-44. Epub 2013 Jul 24.

Corresponding Author: Michael Weinfeld, Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB, Canada, T6G 1Z2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-1093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793902PMC
October 2013

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.

Clin Cancer Res 2013 Oct 6;19(19):5485-93. Epub 2013 Aug 6.

Authors' Affiliations: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; The Cancer Research UK Gene Function Laboratory; Breakthrough Breast Cancer Research Center; Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; University of California San Francisco, San Francisco, California; Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; The Chaim Sheba Medical Center, Tel Hashomer, Israel; Princess Margaret Hospital, Toronto, Canada; Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and Dana Farber Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1262DOI Listing
October 2013

Sit4p/PP6 regulates ER-to-Golgi traffic by controlling the dephosphorylation of COPII coat subunits.

Mol Biol Cell 2013 Sep 17;24(17):2727-38. Epub 2013 Jul 17.

Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California at San Diego, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1091/mbc.E13-02-0114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756924PMC
September 2013

BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.

Clin Cancer Res 2013 Sep 23;19(18):5003-15. Epub 2013 Jul 23.

Authors' Affiliations: BioMarin Pharmaceutical Inc., Novato, California; Cancer Research UK Gene Function Laboratory; and The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-1391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485449PMC
September 2013

Identification of miRNA modulators to PARP inhibitor response.

DNA Repair (Amst) 2013 Jun 6;12(6):394-402. Epub 2013 Apr 6.

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2013.02.003DOI Listing
June 2013

The highly conserved COPII coat complex sorts cargo from the endoplasmic reticulum and targets it to the golgi.

Cold Spring Harb Perspect Biol 2013 Feb 1;5(2). Epub 2013 Feb 1.

Department of Cellular and Molecular Medicine, Howard Hughes Medical Institute, University of California at San Diego, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a013367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552504PMC
February 2013

Tankyrase-targeted therapeutics: expanding opportunities in the PARP family.

Nat Rev Drug Discov 2012 Dec;11(12):923-36

The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd3868DOI Listing
December 2012

Endoscopic endonasal pituitary surgery: impact of surgical education on operation length and patient morbidity.

J Neurol Surg B Skull Base 2012 Dec 14;73(6):405-9. Epub 2012 Nov 14.

Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0032-1329620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3578591PMC
December 2012

The promise of combining inhibition of PI3K and PARP as cancer therapy.

Cancer Discov 2012 Nov;2(11):982-4

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0433DOI Listing
November 2012

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.

EMBO Mol Med 2012 Oct 30;4(10):1087-96. Epub 2012 Aug 30.

The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK.

View Article

Download full-text PDF

Source
http://embomolmed.embopress.org/cgi/doi/10.1002/emmm.2012012
Publisher Site
http://dx.doi.org/10.1002/emmm.201201250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491838PMC
October 2012